Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name MALAT1
   Synonyms MALAT1, HCN, LINC00047, NCRNA00047, NEAT2, PRO2853, PRO1073, MALAT-1, mascRNA
   Region GRCh38_11:65497688-65506516    Sequence
   Ensembl ENSG00000251562
   RefSeq NR_002819
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name hepatocellular carcinoma
   ICD-0-3 C22.0  M8170/3
   Methods qPCR, RNAi, Western blot, Dual-luciferase reporter assay etc.
   Sample cell lines (BEL-7402, BEL-7402/5-FU)
   Expression Pattern up-regulated
   Function Description

The results showed that MALAT1 was over two times higher in BEL-7402/5-FU cells than in BEL-7402 cells. It was HIF-2a, but not HIF-1a induced MALAT1 upregulation in HCC cells. Dual luciferase assay demonstrated that there were at least two binding sites of miR-26b in MALAT1. Therefore, we infer that there is a HIF-2a-MALAT1-miR-216b axis in HCC cells. Cell viability assay showed that both MALAT1 siRNA and miR-216b mimics reduced IC50 of 5-FU, ADR and MMC in BEL-7402/5-FU cells. MALAT1 siRNA and miR-216b mimics showed similar effect as 3-MA on reducing LC3-II levels, inhibiting p62 degradation and suppressing GFP-LC3 puncta formation in BEL-7402/5-FU cells.

   Pubmed ID 27524242
   Year 2016
   Title The HIF-2a-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy.
   External Links
   Links for  MALAT1 GenBank       HGNC       lncrnadb       Noncode
   Links for  hepatocellular carcinoma Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.